Nephrogenic systemic fibrosis is a rare, potentially life-threatening condition in which the skin and internal organs develop progressive scarring, triggered by exposure to certain gadolinium-based contrast agents used in MRI scans. The disease occurs almost exclusively in people with severely reduced kidney function. First identified in 1997, NSF went from an obscure dermatological curiosity to a major patient-safety concern within a decade, reshaped how radiologists worldwide use contrast dyes, and has since been nearly eliminated through screening protocols and safer contrast formulations.
What Causes NSF
The root cause is gadolinium, a heavy metal used in the contrast agents that make MRI images clearer. In people with healthy kidneys, these agents are filtered out of the bloodstream within hours. In people whose kidneys are failing, the agent lingers in the body for days or even weeks. During that extended exposure, the gadolinium can separate from the chemical cage (called a chelate) that keeps it stable and nontoxic. Once free gadolinium ions are released into the tissues, they appear to trigger a fibrotic response, essentially telling the body’s connective-tissue cells to overproduce collagen and other structural proteins.
Not all gadolinium-based contrast agents carry the same risk. The agents differ in their chemical structure and in how tightly they hold onto the gadolinium ion. Linear agents, which wrap around gadolinium in a chain-like fashion, tend to release free gadolinium more readily than macrocyclic agents, which lock the metal inside a ring-shaped cage. Whether an agent is ionic or nonionic also affects its stability. These differences in stability are thought to explain why certain agents have been linked to far more NSF cases than others.1Journal of the American College of Radiology. Gadolinium-Containing MRI Contrast Agents: Important Variations on a Theme for NSF
Laboratory work supports this picture. When fibroblasts (the cells responsible for producing connective tissue) were exposed to gadolinium from less-stable chelates, they ramped up production of fibronectin, transforming growth factor-β, and the stress-fiber protein that marks an activated scar-forming cell. The response was dose-dependent: more free gadolinium meant more fibrotic activity.2PubMed Central. Type of MRI contrast, tissue gadolinium, and fibrosis What makes the link especially convincing is that gadolinium has been found deposited directly in the skin of affected patients. In one study covering 29 patients, gadolinium was detected in the skin biopsies of all of them, concentrated in the deep layers of the dermis and in subcutaneous tissue, often bound to calcium and phosphorus.3PubMed. Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis
Symptoms and How the Disease Progresses
NSF typically begins in the extremities. The earliest signs are swelling, redness, and a burning or itching sensation in the skin of the legs or arms. Over days to weeks, the affected areas develop firm, thickened plaques that can range from reddish to darkly pigmented. As the fibrosis advances, the skin becomes woody and tight, eventually tethering itself to the tissue underneath so that it can no longer be pinched or moved freely.4PubMed Central. Nephrogenic systemic fibrosis: current concepts
The clinical appearance varies more than early reports suggested. Some patients develop the classic widespread hardening, while others present with localized linear plaques that look quite different. Biopsy findings also span a wide range: collagen bundles can be thin or thick, mucin deposits scant or abundant, and calcification or even bone formation within the skin has been documented in some cases.5PubMed. Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling This variability means that a mild case and a severe case can look strikingly different both clinically and under the microscope.
Roughly half of NSF patients go on to develop joint contractures, where the fibrosis tightens the tissue around joints so much that they can no longer fully extend. About one in twenty of those patients become so severely restricted that walking and basic daily activities are compromised.6Annals of Rehabilitation Medicine. A Case of Delayed Onset Nephrogenic Systemic Fibrosis After Gadolinium Based Contrast Injection Pain, weakness, and the progressive loss of independence can be devastating. In severe cases, some patients end up wheelchair-bound, reporting substantially diminished quality of life from combined pain, restricted movement, and psychological distress.7PubMed Central. Nephrogenic systemic fibrosis-related pulmonary restriction: An under-appreciated manifestation potentially reversible with imatinib therapy
When the Fibrosis Spreads Beyond the Skin
The name “nephrogenic systemic fibrosis” was deliberately chosen to replace the earlier term “nephrogenic fibrosing dermopathy” once it became clear that the disease is not limited to the skin. The fibrotic process can infiltrate deeper structures: subcutaneous fat, fascia, and skeletal muscle. In some patients studied at biopsy or autopsy, fibrosis was found in the lungs, the myocardium (heart muscle), and the pericardium (the sac around the heart), as well as the diaphragm.8PubMed. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin Several patients in early case series showed severe woody induration of the muscles in the legs, thighs, and forearms, suggesting the deep-tissue involvement can be extensive.
Involvement of the lungs is worth particular attention. Fibrosis of the chest wall, diaphragm, or lung tissue itself can restrict breathing. Because these patients already carry the burden of kidney failure and often other comorbidities, respiratory restriction from NSF may go under-recognized, attributed to other causes rather than being flagged as part of the fibrotic disease.9PubMed Central. Nephrogenic systemic fibrosis-related pulmonary restriction: An under-appreciated manifestation potentially reversible with imatinib therapy Internal organ involvement is what makes NSF potentially fatal, distinguishing it from a condition that might otherwise seem like a severe but survivable skin disease.10PubMed. Nephrogenic systemic fibrosis
Distinguishing NSF From Lookalike Conditions
NSF can be mistaken for several other fibrosing disorders, and getting the diagnosis right matters because the cause and management differ sharply. The conditions most commonly confused with NSF include scleroderma (systemic sclerosis), scleromyxedema, scleredema, eosinophilic fasciitis, and graft-versus-host disease.11PubMed Central. Nephrogenic systemic fibrosis: current concepts
A few distinguishing features help clinicians separate NSF from these mimics. The distribution of skin involvement is a strong clue: NSF preferentially affects the limbs and trunk but spares the face, while scleroderma commonly involves facial skin. NSF also lacks the autoimmune blood markers (such as anti-Scl-70 or anticentromere antibodies) seen in systemic sclerosis. And the histopathology of NSF, with its characteristic proliferation of certain dendritic cells and a distinctive pattern of collagen and mucin deposition, looks different under the microscope from what a pathologist would see in scleroderma or eosinophilic fasciitis.12PubMed. Nephrogenic systemic fibrosis: an unusual scleroderma-like fibrosing disorder Critically, the clinical context matters: NSF should be considered whenever a patient with chronic kidney disease and a history of gadolinium exposure develops unexplained skin thickening, and a skin biopsy is the standard confirmatory step.
Why New Cases Have Nearly Disappeared
NSF went from a growing concern to a near-eliminated disease remarkably fast. The turning point came around 2006 to 2008, when the link between specific gadolinium agents and NSF was widely publicized and regulatory bodies issued safety warnings. Since then, new confirmed cases have dropped to virtually zero in most settings.13Journal of Cardiovascular Magnetic Resonance. Minimizing Risk of Nephrogenic systemic fibrosis in Cardiovascular Magnetic Resonance
The decline resulted from several coordinated changes. Hospitals stopped using the highest-risk agents (the so-called group I agents, predominantly linear chelates like gadodiamide and gadopentetate dimeglumine) in patients with kidney disease, switching to the more stable group II and group III agents. Screening protocols were introduced to check kidney function before contrast-enhanced MRI scans. And when contrast was deemed necessary for a patient on dialysis, prompt post-scan dialysis sessions were arranged to help clear the agent from the body. One institution documented the impact directly: before switching agents and implementing screening, six out of 246 patients with severely reduced kidney function developed NSF over a one-year period. After the switch, zero out of 1,423 such patients developed the disease over nearly eight years.14PubMed. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide
A joint consensus statement from the American College of Radiology and the National Kidney Foundation analyzed pooled data on group II agents in high-risk patients and found zero NSF events following nearly 5,000 administrations to patients with severely impaired kidney function. No unconfounded cases have been reported for the only available group III agent either.15PubMed. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation Through all of these measures, NSF has been largely eliminated, though the older group I agents still carry formal warnings.16PubMed. Update on Gadolinium-Based Contrast Agent Safety, From the AJR Special Series on Contrast Media
Treatment Options for People Already Affected
There is no established cure for NSF, and managing the disease remains difficult. The treatments that have been tried are varied and largely supported by individual case reports and small open-label trials rather than large randomized studies. This is partly because NSF is rare and partly because the affected population, patients with end-stage kidney disease, complicates trial design.
The most studied pharmacological option is imatinib mesylate, a drug originally developed for certain cancers that also has anti-fibrotic properties. In a small clinical trial, patients treated with imatinib showed meaningful reductions in skin thickening scores, though the improvement in joint mobility was limited.17PubMed. Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial A separate report found that stopping the drug led to recurrence within weeks, and restarting it brought improvement back, reinforcing that the effect is real but requires ongoing treatment. Biopsies taken before and after treatment showed less fibrosis, but the gadolinium deposited in the tissues remained unchanged, meaning imatinib suppresses the fibrotic process without clearing its cause.18PubMed. Imatinib mesylate treatment of nephrogenic systemic fibrosis
Restoring kidney function is the intervention that seems to produce the most durable benefit. Kidney transplantation has been reported to improve NSF symptoms, with patients regaining mobility and seeing clinical improvement in skin lesions. One case report described a physically debilitated patient who became ambulatory after transplantation. Even when the transplanted kidney later declined in function, the NSF improvements persisted, suggesting that a period of improved renal clearance may help the body process some of the retained gadolinium or interrupt the fibrotic cascade.19Nephrology Dialysis Transplantation. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature Other modalities that have been tried with varying results include plasmapheresis, extracorporeal photopheresis, and sodium thiosulfate, but none has enough evidence behind it to be considered standard care.
Screening and Dialysis Before a Contrast MRI
Because prevention has been far more successful than treatment, the practical question for patients with kidney disease is what happens before a contrast-enhanced MRI. Current practice at most institutions involves checking kidney function, typically through a blood test estimating glomerular filtration rate (eGFR), before administering any gadolinium-based agent. The threshold that raises concern is generally an eGFR below 30, which corresponds to stage 4 or 5 chronic kidney disease. Some institutions use a brief screening questionnaire to identify patients who need the blood test, which can save time and cost in settings where not every patient’s lab work is readily available.20AJR Am J Roentgenol / PubMed Central. Screening patients to assess renal function before administering gadolinium chelates: assessment of the Choyke questionnaire
For patients already on dialysis who need a contrast-enhanced MRI, the standard recommendation is to schedule a hemodialysis session soon after the scan to help remove the contrast agent. Hemodialysis clears gadolinium-based agents relatively efficiently. Peritoneal dialysis, by contrast, achieves clearance rates roughly 40-fold lower, making it far less effective for this purpose.21American Journal of Kidney Diseases. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Recommendations From the American College of Radiology Council on Quality and Safety That said, guidelines caution against starting dialysis or switching a patient from peritoneal dialysis to hemodialysis solely to reduce NSF risk, since dialysis itself carries risks and the evidence that it actually prevents NSF is not definitive.22PubMed. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists
Gadolinium Deposition in the Brain
While NSF drew attention to gadolinium’s dangers in kidney patients, a newer concern has emerged that affects people with perfectly normal kidneys. Beginning around 2014, researchers noticed that patients who had undergone multiple contrast-enhanced MRI scans showed unusual bright spots on subsequent unenhanced brain scans, particularly in the dentate nuclei and globus pallidus. Autopsy and biopsy studies confirmed that gadolinium was being deposited in brain tissue. In one study, neuronal tissue from patients who had received contrast showed gadolinium concentrations ranging from 0.1 to 58.8 micrograms per gram, with levels correlating to the number of prior contrast doses, while control patients had undetectable levels.23PubMed. Intracranial Gadolinium Deposition after Contrast-enhanced MR Imaging
This deposition appears to happen even with macrocyclic agents, which are the ones considered safer for NSF prevention, though linear agents seem to cause more pronounced signal changes on imaging.24The Lancet Neurology. Recommendations for the clinical and research use of gadolinium-based contrast agents The findings have prompted a fresh round of scrutiny around the entire class of gadolinium-based agents, not just for kidney patients but for anyone receiving repeated doses.25PubMed Central. Gadolinium based contrast agents in current practice: Risks of accumulation and toxicity in patients with normal renal function Whether brain deposition causes any clinical symptoms remains an open question; so far, no clear neurological harm has been definitively linked to it. But the mere presence of a heavy metal accumulating in the brain with each scan has understandably made both patients and physicians more cautious about ordering contrast-enhanced MRIs when they are not strictly necessary.
Legal Fallout and the Litigation Landscape
NSF generated significant litigation, primarily directed at the manufacturers of the gadolinium-based contrast agents most strongly linked to the disease. The legal focus was largely on product labeling: whether manufacturers provided adequate warnings about the risk in patients with kidney disease, and whether they acted quickly enough once the association became apparent.26PubMed. Nephrogenic systemic fibrosis and gadolinium-based contrast: medico-legal implications The wave of lawsuits contributed to the speed with which manufacturers updated their labels and regulatory agencies issued warnings. For patients who developed NSF before the risks were widely recognized, the litigation remains a complicated legacy, one in which outcomes vary depending on when exposure occurred relative to the evolving state of medical knowledge.
Beyond the courtroom, NSF reshaped institutional practices around informed consent. Radiology departments now routinely disclose the risks of gadolinium contrast to patients with impaired kidney function, and many have built automated alerts into their electronic ordering systems that flag patients with low eGFR before a contrast-enhanced scan can be scheduled. The disease, though nearly eradicated, left a lasting imprint on how the medical system handles contrast safety.